According to the findings of a report by Grand View Research, Inc.; the global intravenous immunoglobulin (IVIG) market is projected to attain a valuation of around USD 10.9 billion by 2022. Increasing cases of immunodeficiency diseases owing to unhealthy lifestyle can propel the IVIG over the forecast period (2012 to 2022). IVIG therapies can enable quick response upon administration and recovery of patients without any side effects.
Rising cases of immunodeficiency cases may boost the growth of the market for intravenous immunoglobulin in the forthcoming years. Increasing use of off-label indications coupled with adoption of IVIG-based treatments can further fuel the market in the coming years. Sedentary lifestyle, limited physical activities, and consumption of alcohol and foods with high saturated fats, salt, and sugar can positively influence the market in near future. High prevalence of lifestyle related health conditions such as antibody deficiency disorders and obesity is expected to fuel market growth during the forecast period.
The worldwide intravenous immunoglobulin (IVIG) market can be segregated on the basis of application, administration, and region. Based on application, the market can be classified into immunodeficiency diseases, congenital AIDS, chronic inflammatory demyelinating polyneuropathy (CIPD), hypogammaglobulinemia, chronic lymphocytic leukemia, myasthenia gravis, Kawasaki disease, Guillain-Barre syndrome, and idiopathic thrombocytopenic purpura.
In 2014, hypogammaglobulinemia segment dominated the market with around 21.1% of total market share in terms of revenue. Rising cases of primary immunodeficiency diseases (PID) can spur segment growth over the forecast period. In addition, the CIPD segment is expected to emerge as the second largest segment in terms of market share owing to its occurrence in patients with diabetes mellitus. Steroids, immunosuppressive drugs, and plasmapheresis can be used to treat CIPD. Still, IVIG is expected to be an effective and long-lasting alternative overall conventional treatments. Administration of intravenous immunoglobulin is minimally invasive, safe, and user-friendly. These factors are likely to impel demand for these advanced treatments in the coming years.
Based on administration, the market can be bifurcated into intravenous and subcutaneous. In 2014, the intravenous segment accounted for the maximum revenue share owing to increasing use of intravenous immunoglobulin in various immunology applications. In addition, growing awareness regarding autoimmune diseases coupled with rising healthcare expenditure can fuel growth of this segment over the forecast period. Moreover, regular clinical trials for new applications coupled with rising number of approvals for intravenous products can also support growth during next few years.
Access Full research report on IVIG Market analysis: https://www.grandviewresearch.com/industry-analysis/intravenous-immunoglobulin-market
On the other hand, subcutaneous administration segment can grow at a remarkable CAGR of nearly 9.8% during the forecast period. Rising incorporation of subcutaneous immunoglobulins to treat pelvic inflammatory diseases (PIDs) is expected to boost this expansion. In addition, potential benefits such as quick response and fewer side effects can further fuel demand for subcutaneous administration in the coming years. Moreover, high preference for subcutaneous immunoglobulin in home-based self-infusion immunotherapy can foster the demand over the forecast period.
Regional segmentation includes Europe, North America, Asia Pacific, Latin America, Middle East and Africa (MEA). In 2014, North America dominated the market while accounting for 47.7% of revenue share. Growing awareness regarding products available to treat immunodeficiency diseases can influence demand. In addition, inclination of clinicians towards such therapies coupled with increasing healthcare expenditure can impel market growth. Moreover, rising number of geriatric population prone to chronic diseases and changing lifestyle can fuel demand for IVIG therapies in the region.
The Asia Pacific market is expected to witness significant growth during the forecast period owing to increasing adoption of immunoglobulin therapies to treat immune deficiencies. In addition, growing number of geriatric population can influence market growth. Moreover, high healthcare expenditure owing to improvement in facilities can stimulate regional product demand.
View more reports of this category by Grand View Research at:
The Europe market for intravenous immunoglobulin is estimated to display impressive CAGR of over 6% during the forecast period owing to high prevalence of CIPD patients in the region. In addition, rising cases of patients suffering from bleeding disorders can further influence product demand in the coming years.
Some of the leading companies in the global intravenous immunoglobulin (IVIG) market are Biotest AG; Grifols; Baxter International Inc.; Octapharma AG; and LFB Biotechnologies. Most companies are expected to be involved in extensive R&D activities to develop innovative and cost-effective immunoglobulin therapies. In addition, few key players are likely to adopt strategies such as mergers and acquisitions to maintain their market position over competitors.
Browse Press Release of this Report: https://www.grandviewresearch.com/press-release/global-ivig-market
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
Country: United States